A potential therapeutic strategy for malignant mesothelioma with gene medicine

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Tada, Yuji ^a   Shimada, Hideaki ^b   Hiroshima, Kenzo ^c   Tagawa, Masatoshi ^a,d  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Women s Medical University   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2B INTERFERON; ANTIBODY; ANTIVECTOR ANTIBODY; ASBESTOS; BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; HERPES SIMPLEX VIRUS THYMIDINE KINASE; INTERLEUKIN 2; NAVELBINE; PEMETREXED; RALTITREXED; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; CARCINOGEN;

CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; DRUG SAFETY; GENE EXPRESSION; GENE MEDICINE; GENE VECTOR; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LUNG RESECTION; MALIGNANT MESOTHELIOMA; METASTASIS; NONHUMAN; OCCUPATIONAL EXPOSURE; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PLEURECTOMY; QUALITY OF LIFE; REVIEW; THORACIC CAVITY; TRANSGENE; VIRUS INFECTIVITY; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; GENE THERAPY; GENETICS; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; ADENOVIRIDAE; LUNG NEOPLASMS; TOXICITY;

ADENOVIRIDAE; ANIMALS; ASBESTOS; CARCINOGENS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM METASTASIS; TRANSGENES;

EID: 84874625850     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/572609     Document Type: Review

References (58)

1. Robinson B. W. S., Lake R. A., Advances in malignant mesothelioma. The New England Journal of Medicine 2005 353 15 1591 1603 2-s2.0-26444458845 10.1056/NEJMra050152 (Pubitemid 41434638)
2. Robinson B. W. S., Musk A. W., Lake R. A., Malignant mesothelioma. The Lancet 2005 366 9483 397 408 2-s2.0-23044436187 10.1016/S0140-6736(05)67025-0 (Pubitemid 41073959)
3. Fennell D. A., Gaudino G., O'Byrne K. J., Mutti L., van Meerbeeck J., Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Cardiovascular Medicine 2008 5 3 136 147 2-s2.0-40249088552 10.1038/ncpcardio1089 (Pubitemid 351330666)
4. Vogelzang N. J., Rusthoven J. J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., Paoletti P., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2003 21 14 2636 2644 2-s2.0-0041629528 10.1200/JCO.2003.11.136 (Pubitemid 46606305)
5. Santoro A., O'Brien M. E., Stahel R. A., Nackaerts K., Baas P., Karthaus M., Eberhardt W., Paz-Ares L., Sundstrom S., Liu Y., Ripoche V., Blatter J., Visseren-Grul C. M., Manegold C., Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program. Journal of Thoracic Oncology 2008 3 7 756 763 2-s2.0-50349092664 10.1097/JTO.0b013e31817c73d6
6. van Meerbeeck J. P., Gaafar R., Manegold C., van Klaveren R. J., van Marck E. A., Vincent M., Legrand C., Bottomley A., Debruyne C., Giaccone G., Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. Journal of Clinical Oncology 2005 23 28 6881 6889 2-s2.0-27244447448 10.1200/JCO.20005.14.589
7. Ceresoli G. L., Zucali P. A., Gianoncelli L., Lorenzi E., Santoro A., Second-line treatment for malignant pleural mesothelioma. Cancer Treatment Reviews 2010 36 1 24 32 2-s2.0-74649084445 10.1016/j.ctrv.2009.09.003
8. Krug L. M., Pass H. I., Rusch V. W., Kindler H. L., Sugarbaker D. J., Rosenzweig K. E., Flores R., Friedberg J. S., Pisters K., Monberg M., Obasaju C. K., Vogelzang N. J., Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Journal of Clinical Oncology 2009 27 18 3007 3013 2-s2.0-67650002101 10.1200/JCO.2008.20.3943
9. Garland L. L., Rankin C., Gandara D. R., Rivkin S. E., Scott K. M., Nagle R. B., Klein-Szanto A. J. P., Testa J. R., Altomare D. A., Borden E. C., Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. Journal of Clinical Oncology 2007 25 17 2406 2413 2-s2.0-34347273808 10.1200/JCO.2006.09.7634 (Pubitemid 46999211)
10. Yano S., Li Q., Wang W., Yamada T., Takeuchi S., Nakataki E., Ogino H., Goto H., Nishioka Y., Sone S., Antiangiogenic therapies for malignant pleural mesothelioma. Frontiers in Bioscience 2011 16 740 748 2-s2.0-79955020053 10.2741/3716
11. Dowell J. E., Dunphy F. R., Taub R. N., A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012 77 3 567 571 10.1016/j.lungcan.2012.05.111
12. Lee A. Y., Ras D. J., He B., Jablons D. M., Update on the molecular biology of malignant mesothelioma. Cancer 2007 109 8 1454 1461 2-s2.0-34247146844 10.1002/cncr.22552 (Pubitemid 46595678)
13. Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R. A., Felley-Bosco E., Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009 64 2 140 147 2-s2.0-63049127084 10.1016/j.lungcan.2008.08.014
14. Testa J. R., Cheung M., Pei J., Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics 2011 43 10 1022 1025 10.1038/ng.912
15. Yang C. T., You L., Yeh C. C., Chang J. W. C., Zhang F., McCormick F., Jablons D. M., Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. Journal of the National Cancer Institute 2000 92 8 636 641 2-s2.0-0034685531 (Pubitemid 30321306)
16. INK4a adenovirus. Cancer Gene Therapy 2000 7 11 1421 1425 2-s2.0-0033664624
17. ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Research 2001 61 16 5959 5963 2-s2.0-0035881594 (Pubitemid 32762521)
18. Yang C. T., You L., Lin Y. C., Lin C. L., McCormick F., Jablons D. M., A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Research 2003 23 1 33 38 2-s2.0-0344405743 (Pubitemid 36358497)
19. Li Q., Kawamura K., Yamanaka M., Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Therapy 2012 19 3 218 228 10.1038/cgt.2011.86
20. Matsumoto K., Nakamura T., NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Science 2003 94 4 321 327 2-s2.0-0037850880 10.1111/j.1349-7006.2003.tb01440.x (Pubitemid 36626362)
21. Suzuki Y., Sakai K., Ueki J., Xu Q., Nakamura T., Shimada H., Nakamura T., Matsumoto K., Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. International Journal of Cancer 2010 127 8 1948 1957 2-s2.0-77956992010 10.1002/ijc.25197
22. Sakai K., Nakamura T., Matsumoto K., Nakamura T., Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. The Journal of Biological Chemistry 2009 284 33 22491 22499 2-s2.0-69249088890 10.1074/jbc.M109.025148
23. Pesonen S., Diaconu I., Kangasniemi L., Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Research 2012 72 7 1621 1631 10.1158/0008-5472.CAN-11-3001
24. Kawasaki Y., Tamamoto A., Takagi-Kimura M., Maeyama Y., Yamaoka N., Terada N., Okamura H., Kasahara N., Kubo S., Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Therapy 2011 18 8 571 578 2-s2.0-79960556047 10.1038/cgt.2011.25
25. Adusumilli P. S., Stiles B. M., Chan M. K., Mullerad M., Eisenberg D. P., Ben-Porat L., Huq R., Rusch V. W., Fong Y., Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. Journal of Gene Medicine 2006 8 5 603 615 2-s2.0-33744827944 10.1002/jgm.877 (Pubitemid 43827253)
26. Li H., Peng K. W., Dingli D., Kratzke R. A., Russell S. J., Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Therapy 2010 17 8 550 558 2-s2.0-77954814628 10.1038/cgt.2010.10
27. Yamanaka M., Tada Y., Kawamura K., E1B-55kD-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents. Journal of Thoracic Oncology 2012 7 12 1850 1857 10.1097/JTO.0b013e3182725fa4
28. Tada Y., Takiguchi Y., Hiroshima K., Shimada H., Ueyama T., Nakamura M., Tatsumi K., Kuriyama T., Tagawa M., Gene therapy for malignant pleural mesothelioma: present and future. Oncology Research 2008 17 6 239 246 2-s2.0-61449113085 10.3727/096504008786991602
29. Sterman D. H., Treat J., Litzky L. A., Amin K. M., Coonrod L., Molnar-Kimber K., Recio A., Knox L., Wilson J. M., Albelda S. M., Kaiser L. R., Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Therapy 1998 9 7 1083 1092 2-s2.0-17344365922 (Pubitemid 28236516)
30. Mukherjee S., Haenel T., Himbeck R., Scott B., Ramshaw I., Lake R. A., Harnett G., Phillips P., Morey S., Smith D., Davidson J. A., Musk A. W., Robinson B., Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Therapy 2000 7 5 663 670 2-s2.0-0034106260 (Pubitemid 30314050)
31. Sterman D. H., Recio A., Carroll R. G., Gillespie C. T., Haas A., Vachani A., Kapoor V., Sun J., Hodinka R., Brown J. L., Corbley M. J., Parr M., Ho M., Pastan I., Machuzak M., Benedict W., Zhang X. Q., Lord E. M., Litzky L. A., Heitjan D. F., June C. H., Kaiser L. R., Vonderheide R. H., Albelda S. M., A phase I clinical trial of single-dose intrapleural IFN- β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clinical Cancer Research 2007 13 15 4456 4466 2-s2.0-34547692979 10.1158/1078-0432.CCR-07-0403 (Pubitemid 47219714)
32. Sterman D. H., Recio A., Haas A. R., Vachani A., Katz S. I., Gillespie C. T., Cheng G., Sun J., Moon E., Pereira L., Wang X., Heitjan D. F., Litzky L., June C. H., Vonderheide R. H., Carroll R. G., Albelda S. M., A phase I trial of repeated intrapleural adenoviral-mediated interferon- β gene transfer for mesothelioma and metastatic pleural effusions. Molecular Therapy 2010 18 4 852 860 2-s2.0-77950517811 10.1038/mt.2009.309
33. Sterman D. H., Haas A., Moon E., A trial of intrapleural adenoviral-mediated interferon- α 2b gene transfer for malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine 2011 184 12 1395 1399 10.1164/rccm.201103-0554CR
34. Willmon C., Diaz R. M., Wongthida P., Galivo F., Kottke T., Thompson J., Albelda S., Harrington K., Melcher A., Vile R., Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Molecular Therapy 2011 19 1 140 149 2-s2.0-78650880193 10.1038/mt.2010.224
35. Saito A., Morishita N., Mitsuoka C., Kitajima S., Hamada K., Lee K. M., Kawabata M., Fujisawa M., Shirakawa T., Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model. Journal of Gene Medicine 2011 13 6 353 361 2-s2.0-79959730726 10.1002/jgm.1578
36. Grekova S. P., Aprahamian M., Daeffler L., Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biology & Therapy 2011 12 10 888 895 10.4161/cbt.12.10.17678
37. Melotti A., Daga A., Marubbi D., Zunino A., Mutti L., Corte G., In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer 2010 10, article 54 2-s2.0-77649294054 10.1186/1471-2407-10-54
38. Iguchi K., Sakurai F., Tomita K., Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. Cancer Gene Therapy 2012 19 2 118 125 10.1038/cgt.2011.74
39. Gros A., Puig C., Guedan S., Rojas J. J., Alemany R., Cascallo M., Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Molecular Therapy 2010 18 5 903 911 2-s2.0-77952009437 10.1038/mt.2010.22
40. Koski A., Raki M., Nokisalmi P., Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Molecular Therapy 2012 20 1 221 229 10.1038/mt.2011.230
41. Seth P., Wang Z. G., Pister A., Zafar M. B., Kim S., Guise T., Wakefield L., Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor- β receptor II and human immunoglobulin Fc for breast cancer therapy. Human Gene Therapy 2006 17 11 1152 1160 2-s2.0-33750979574 10.1089/hum.2006.17.1152 (Pubitemid 44749716)
42. Lavilla-Alonso S., Bauer M. M., Abo-Ramadan U., Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Therapy 2012 19 2 126 134 10.1038/cgt.2011.76
43. Watanabe Y., Kojima T., Kagawa S., Uno F., Hashimoto Y., Kyo S., Mizuguchi H., Tanaka N., Kawamura H., Ichimaru D., Urata Y., Fujiwara T., A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 2010 29 8 1145 1154 2-s2.0-77649192334 10.1038/onc.2009.415
44. Cheng J., Sauthoff H., Huang Y., Kutler D. I., Bajwa S., Rom W. N., Hay J. G., Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Molecular Therapy 2007 15 11 1982 1990 2-s2.0-35548977113 10.1038/sj.mt.6300264 (Pubitemid 350011738)
45. Kim J. H., Lee Y. S., Kim H., Huang J. H., Yoon A. R., Yun C. O., Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. Journal of the National Cancer Institute 2006 98 20 1482 1493 2-s2.0-33750207622 10.1093/jnci/djj397 (Pubitemid 44605593)
46. Mookerjee I., Solly N. R., Royce S. G., Tregear G. W., Samuel C. S., Tang M. L. K., Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease. Endocrinology 2006 147 2 754 761 2-s2.0-30944442868 10.1210/en.2005-1006 (Pubitemid 43112991)
47. Willmon C. L., Saloura V., Fridlender Z. G., Wongthida P., Diaz R. M., Thompson J., Kottke T., Federspiel M., Barber G., Albelda S. M., Vile R. G., Expression of IFN- β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Research 2009 69 19 7713 7720 2-s2.0-70350230280 10.1158/0008-5472.CAN-09-1013
48. Li B., Liu X., Fan J., Qi R., Bo L., Gu J., Qian Q., Qian C., Liu X., A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral in vivo. Journal of Gene Medicine 2006 8 10 1232 1242 2-s2.0-33750526892 10.1002/jgm.953 (Pubitemid 44660522)
49. Zhu Z. B., Makhija S. K., Lu B., Wang M., Wang S., Takayama K., Siegal G. P., Reynolds P. N., Curiel D. T., Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. Journal of Thoracic Oncology 2006 1 7 701 711 2-s2.0-34247893974 (Pubitemid 47163960)
50. Oshima Y., Yajima S., Yamazaki K., Matsushita K., Tagawa M., Shimada H., Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Annals of Thoracic and Cardiovascular Surgery 2010 16 6 389 393 2-s2.0-78751640261
51. Kubo S., Kawasaki Y., Yamaoka N., Tagawa M., Kasahara N., Terada N., Okamura H., Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. Journal of Gene Medicine 2010 12 8 681 692 2-s2.0-77956646669 10.1002/jgm.1486
52. van der Bij S., Schaake E., Koffijberg H., Burgers J. A., de Mol B. A. J. M., Moons K. G. M., Markers for the non-invasive diagnosis of mesothelioma: a systematic review. British Journal of Cancer 2011 104 8 1325 1333 2-s2.0-79954434468 10.1038/bjc.2011.104
53. Mimura T., Ito A., Sakuma T., Ohbayashi C., Yoshimura M., Tsubota N., Okita Y., Okada M., Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007 109 5 933 938 2-s2.0-33847391263 10.1002/cncr.22477 (Pubitemid 46333535)
54. Hollevoet K., Reitsma J. B., Creaney J., Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Journal of Clinical Oncology 2012 30 13 1541 1549 10.1200/JCO.2011.39.6671
55. Dong F., Wang L., Davis J. J., Hu W., Zhang L., Guo W., Teraishi F., Ji L., Fang B., Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor- α -related apoptosis-inducing ligand-armed oncolytic adenovirus. Clinical Cancer Research 2006 12 17 5224 5230 2-s2.0-33749011709 10.1158/1078-0432.CCR-06-0244 (Pubitemid 44453352)
56. Zhang Y. A., Nemunaitis J., Samuel S. K., Chen P., Shen Y., Tong A. W., Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Research 2006 66 19 9736 9743 2-s2.0-33750321708 10.1158/0008-5472.CAN-06-1617 (Pubitemid 44623675)
57. He X. P., Su C. Q., Wang X. H., Pan X., Tu Z. X., Gong Y. F., Gao J., Liao Z., Jin J., Wu H. Y., Man X. H., Li Z. S., E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Letters 2009 285 1 89 98 2-s2.0-70349286016 10.1016/j.canlet.2009.05.006
58. Koski A., Kangasniemi L., Escutenaire S. I., Pesonen S., Cerullo V., Diaconu I., Nokisalmi P., Raki M., Rajecki M., Guse K., Ranki T., Oksanen M., Holm S. L., Haavisto E., Karioja-Kallio A., Laasonen L., Partanen K., Ugolini M., Helminen A., Karli E., Hannuksela P., Pesonen S., Joensuu T., Kanerva A., Hemminki A., Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Molecular Therapy 2010 18 10 1874 1884 2-s2.0-77957571590 10.1038/mt.2010.161